All News
Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease
The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.
Read ArticleIs Gout Protective Against Dementia?
People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.
Read ArticleMaking You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read ArticleWhat is JAKne? (5.6.2022)
Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.
Read ArticleAllopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease
A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD
Read ArticleMale vs. Female Responders (4.15.2022)
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Read ArticleNo Benefit to More Intensive Urate Lowering in Gout
While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.
Read Article
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:


